Two-Year Sapien Data Affirms Durability, And The Importance Of Avoiding Leaks

Mortality rates remained statistically indistinguishable after two years among patients receiving either Edwards Lifesciences’ Sapien transcatheter aortic heart valve or open surgical valve replacement in the firm’s PARTNER trial. Transcatheter aortic valve leaks were highlighted as a primary target for improving survival.

Edwards Lifesciences Corp.’s Sapien transcatheter aortic heart valve has a two-year mortality rate that matches that of open surgical valve replacement, recent data show. And a leading trial investigator suggests the findings offer a possible path to meaningfully reducing, rather than simply matching, mortality rates versus surgery.

More from Clinical Trials

More from R&D